Bortezomib, free base, 100mg
To Order Contact us: lieven@wlsolutions.be
Bortezomib |
||
GP0262-5MG | 5 mg | EUR 112.8 |
Bortezomib |
||
T2399-10mg | 10mg | Ask for price |
Description: Bortezomib |
Bortezomib |
||
T2399-1g | 1g | Ask for price |
Description: Bortezomib |
Bortezomib |
||
T2399-1mg | 1mg | Ask for price |
Description: Bortezomib |
Bortezomib |
||
T2399-50mg | 50mg | Ask for price |
Description: Bortezomib |
Bortezomib |
||
T2399-5mg | 5mg | Ask for price |
Description: Bortezomib |
Bortezomib |
||
100100 | 100.0mg | EUR 90 |
Bortezomib |
||
GP0262-25 | 25 | EUR 216.3 |
Bortezomib |
||
GP0262-5 | 5 | EUR 98.4 |
Bortezomib, 99% |
||
BC010-005 | 5mg | Ask for price |
Bortezomib, 99% |
||
BC010-010 | 10mg | EUR 213.6 |
Bortezomib, 99% |
||
BC010-025 | 25mg | EUR 264 |
Bortezomib, 99% |
||
BC010-050 | 50mg | EUR 327.6 |
Bortezomib, 99% |
||
BC010-500 | 500mg | EUR 724.8 |
(1S,2S)-Bortezomib |
||
T10061-10mg | 10mg | Ask for price |
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
||
T10061-1g | 1g | Ask for price |
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
||
T10061-1mg | 1mg | Ask for price |
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
||
T10061-50mg | 50mg | Ask for price |
Description: (1S,2S)-Bortezomib |
(1S,2S)-Bortezomib |
||
T10061-5mg | 5mg | Ask for price |
Description: (1S,2S)-Bortezomib |
Bortezomib (PS-341) |
||
A2614-10 | 10 mg | EUR 142.8 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib (PS-341) |
||
A2614-100 | 100 mg | EUR 408 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib (PS-341) |
||
A2614-25 | 25 mg | EUR 208.8 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib (PS-341) |
||
A2614-5.1 | 10 mM (in 1mL DMSO) | EUR 135.6 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib (PS-341) |
||
A2614-500 | 500 mg | EUR 1005.6 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib (PS-341) |
||
A2614-S | Evaluation Sample | EUR 97.2 |
Description: Bortezomib (originally codenamed PS-341) is the first therapeutic proteasome inhibitor to the tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. |
Bortezomib-pinanediol |
||
T7854-10mg | 10mg | Ask for price |
Description: Bortezomib-pinanediol |
Bortezomib-pinanediol |
||
T7854-1g | 1g | Ask for price |
Description: Bortezomib-pinanediol |
Bortezomib-pinanediol |
||
T7854-1mg | 1mg | Ask for price |
Description: Bortezomib-pinanediol |
Bortezomib-pinanediol |
||
T7854-50mg | 50mg | Ask for price |
Description: Bortezomib-pinanediol |
Bortezomib-pinanediol |
||
T7854-5mg | 5mg | Ask for price |
Description: Bortezomib-pinanediol |
Bortezomib-pinanediol |
||
565251 | 5.0mg | EUR 265 |
Bortezomib (BTZ) Protein (BSA) |
||
20-abx651876 |
|
|
Bortezomib (BTZ) Protein (OVA) |
||
20-abx651877 |
|
|
BSA Conjugated Bortezomib (BTZ) |
||
4-CPK684Ge11 |
|
|
Description: Recombinant Pan-species Bortezomib expressed in: E.coli |
OVA Conjugated Bortezomib (BTZ) |
||
4-CPK684Ge21 |
|
|
Description: Recombinant Pan-species Bortezomib expressed in: E.coli |
BSA Conjugated Bortezomib (BTZ) |
||
RPU55087-100ug | 100ug | EUR 431.2 |
BSA Conjugated Bortezomib (BTZ) |
||
RPU55087-1mg | 1mg | EUR 1911 |
BSA Conjugated Bortezomib (BTZ) |
||
RPU55087-50ug | 50ug | EUR 336 |
OVA Conjugated Bortezomib (BTZ) |
||
RPU55088-100ug | 100ug | EUR 431.2 |
OVA Conjugated Bortezomib (BTZ) |
||
RPU55088-1mg | 1mg | EUR 1911 |
OVA Conjugated Bortezomib (BTZ) |
||
RPU55088-50ug | 50ug | EUR 336 |
Bortezomib (Proteasome inhibitor) |
||
SIH-328-25MG | 25 mg | EUR 192 |
Description: The substance Bortezomib is a proteasome inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white powder which is soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol. |
Bortezomib (Proteasome inhibitor) |
||
SIH-328-5MG | 5 mg | EUR 138 |
Description: The substance Bortezomib is a proteasome inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is white powder which is soluble in 50 mg/ml DMSO, 35 mg/ml Ethanol. |
KRIBIOLISA Bortezomib (VELCADE) ELISA |
||
KOD1013 | 1 x 96 wells | EUR 1067 |
M2698 free base |
||
407496 | 200.0mg | EUR 2950 |
Biotin-X, free acid:100mg |
||
90053 | 100MG | EUR 158.4 |
Description: Minimum order quantity: 1 unit of 100MG |
Bioin-XX, free acid: (100mg) |
||
90054 | 100MG | EUR 258 |
Description: Minimum order quantity: 1 unit of 100MG |
I-37 free base( 2359690-13-2(free base)) |
||
T8721L-10mg | 10mg | Ask for price |
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
||
T8721L-1g | 1g | Ask for price |
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
||
T8721L-1mg | 1mg | Ask for price |
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
||
T8721L-50mg | 50mg | Ask for price |
Description: I-37 free base( 2359690-13-2(free base)) |
I-37 free base( 2359690-13-2(free base)) |
||
T8721L-5mg | 5mg | Ask for price |
Description: I-37 free base( 2359690-13-2(free base)) |
TMB free base |
||
TB0954 | 1g | EUR 85.06 |
FIPI (free base) |
||
B2372-25 | each | EUR 757.2 |
FIPI (free base) |
||
B2372-5 | each | EUR 235.2 |
THZ1 (Free base) |
||
9664-25 | each | EUR 1227.6 |
THZ1 (Free base) |
||
9664-5 | each | EUR 352.8 |
R406 (free base) |
||
A5880-100 | 100 mg | EUR 1452 |
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
R406 (free base) |
||
A5880-25 | 25 mg | EUR 616.8 |
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
R406 (free base) |
||
A5880-5 | 5 mg | EUR 199.2 |
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
R406 (free base) |
||
A5880-5.1 | 10 mM (in 1mL DMSO) | EUR 316.8 |
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
R406 (free base) |
||
A5880-S | Evaluation Sample | EUR 97.2 |
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
R406(free base) |
||
E1KS1533 | 2mg | EUR 625.2 |
R406 (free base) |
||
HY-11108 | 10mM/1mL | EUR 277.2 |
R406 free base |
||
T2467-10mg | 10mg | Ask for price |
Description: R406 free base |
R406 free base |
||
T2467-1g | 1g | Ask for price |
Description: R406 free base |
R406 free base |
||
T2467-1mg | 1mg | Ask for price |
Description: R406 free base |
R406 free base |
||
T2467-50mg | 50mg | Ask for price |
Description: R406 free base |
R406 free base |
||
T2467-5mg | 5mg | Ask for price |
Description: R406 free base |
SIS3 free base |
||
T12923-10mg | 10mg | Ask for price |
Description: SIS3 free base |
SIS3 free base |
||
T12923-1g | 1g | Ask for price |
Description: SIS3 free base |
SIS3 free base |
||
T12923-1mg | 1mg | Ask for price |
Description: SIS3 free base |
SIS3 free base |
||
T12923-50mg | 50mg | Ask for price |
Description: SIS3 free base |
SIS3 free base |
||
T12923-5mg | 5mg | Ask for price |
Description: SIS3 free base |
FIPI free base |
||
407955 | 200.0mg | EUR 1050 |
K201 free base |
||
414202 | 5.0mg | EUR 288 |
S107 free base |
||
530577 | 100.0mg | EUR 750 |
NG25 free base |
||
562503 | 5.0mg | EUR 485 |
YM158 (free base) |
||
HY-U00355 | 1mg | EUR 2770.8 |
YM158 free base |
||
T10501-10mg | 10mg | Ask for price |
Description: YM158 free base |
YM158 free base |
||
T10501-1g | 1g | Ask for price |
Description: YM158 free base |
YM158 free base |
||
T10501-1mg | 1mg | Ask for price |
Description: YM158 free base |